A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078 · Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
PhasePhase 2
TypeInterventional
Age40 Years – 85 Years
WhereBakersfield, California, United States + 324 more
SponsorUpstream Bio Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts
325 sitesApply